Literature DB >> 21757630

Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease.

Jon D Blumenfeld, Jeffrey Tepler, Andreas Mauer, Barry Coller, Daniel G Bichet, Barry Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21757630      PMCID： PMC3138698          DOI： 10.1182/blood-2011-04-347328

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.

Authors:  Benaya Rozen-Zvi; Dafna Yahav; Mihai Gheorghiade; Asher Korzets; Leonard Leibovici; Uzi Gafter
Journal:  Am J Kidney Dis       Date:  2010-06-09       Impact factor: 8.860

2.  Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines.

Authors:  William L Nichols; Margaret E Rick; Thomas L Ortel; Robert R Montgomery; J Evan Sadler; Barbara P Yawn; Andra H James; Mae B Hultin; Marilyn J Manco-Johnson; Mark Weinstein
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

3.  Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.

Authors:  D G Bichet; M Razi; M Lonergan; M F Arthus; V Papukna; C Kortas; J N Barjon
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

4.  Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.

Authors:  J E Kaufmann; A Oksche; C B Wollheim; G Günther; W Rosenthal; U M Vischer
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

5.  Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Authors:  Vicente E Torres; Esther Meijer; Kyongtae T Bae; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John J Ouyang; Frank S Czerwiec
Journal:  Am J Kidney Dis       Date:  2011-02-17       Impact factor: 8.860

6.  Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults.

Authors:  A C Mauer; N A Khazanov; N Levenkova; S Tian; E M Barbour; C Khalida; J N Tobin; B S Coller
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

7.  Vasopressin directly regulates cyst growth in polycystic kidney disease.

Authors:  Xiaofang Wang; Yanhong Wu; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

8.  Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.

Authors:  Tamio Yamaguchi; Shizuko Nagao; Darren P Wallace; Franck A Belibi; Benjamin D Cowley; Jill C Pelling; Jared J Grantham
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

9.  The effect of ABO blood group on the diagnosis of von Willebrand disease.

Authors:  J C Gill; J Endres-Brooks; P J Bauer; W J Marks; R R Montgomery
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

10.  Epidemiological investigation of the prevalence of von Willebrand's disease.

Authors:  F Rodeghiero; G Castaman; E Dini
Journal:  Blood       Date:  1987-02       Impact factor: 22.113
  10 in total
  1 in total

1.  Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease.

Authors:  Katsuhiko Morimoto; Yasuhiro Akai; Masaru Matsui; Hiroki Yano; Miho Tagawa; Ken-Ichi Samejima; Yoshihiko Saito
Journal:  CEN Case Rep       Date:  2017-01-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.